Stockscreener 앱 받기
0.9639
2.88%
0.027
시간 외 거래:
1.05
0.0861
+8.93%
전일 마감가:
$0.9369
열려 있는:
$0.93
하루 거래량:
362.61K
Relative Volume:
0.37
시가총액:
$49.91M
수익:
-
순이익/손실:
$-81.22M
주가수익비율:
-0.3256
EPS:
-2.96
순현금흐름:
$-74.41M
1주 성능:
+7.46%
1개월 성능:
+27.52%
6개월 성능:
-11.57%
1년 성능:
+2.98%
1일 변동 폭
$0.91
$0.9704
1주일 범위
$0.8578
$0.9704
52주 변동 폭
$0.62
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
명칭
Xilio Therapeutics Inc
전화
617-833-1027
주소
828 WINTER STREET, WALTHAM
XLO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.9639 | 46.45M | 0 | -81.22M | -74.41M | -2.96 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-21 | 개시 | Chardan Capital Markets | Buy |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
| 2021-11-16 | 개시 | Cowen | Outperform |
| 2021-11-16 | 개시 | Guggenheim | Buy |
| 2021-11-16 | 개시 | Morgan Stanley | Overweight |
| 2021-11-16 | 개시 | Raymond James | Outperform |
모두보기
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World
Xilio Therapeutics (NASDAQ:XLO) Upgraded at Wall Street Zen - Defense World
50,086 Shares in Xilio Therapeutics, Inc. (NASDAQ:XLO) Bought by Raymond James Financial Inc. - Defense World
Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart at ASCO 2025, Advancing Tumor-Activated Immuno-Oncology Pipeline - Nasdaq
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewswire
Renaissance Technologies LLC Boosts Holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World
Geode Capital Management LLC Acquires 20,230 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Xilio Therapeutics Awards 5,000 Share Stock Option Grant at $0.755 Per Share to New Employee - Stock Titan
Xilio’s Stacey Davis recruited by Enara - The Pharma Letter
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - The Manila Times
Xilio Therapeutics to Present Updated Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Announces Presentation of Phase 2 Data for Vilastobart and Atezolizumab at 2025 ASCO Annual Meeting - Nasdaq
Phase 2 Trial Results: Novel Tumor-Activated Therapy Shows Promise in Hard-to-Treat Colorectal Cancer - Stock Titan
Raymond James Financial Inc. Takes Position in Xilio Therapeutics, Inc. (NASDAQ:XLO) - The AM Reporter
Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com India
Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Expands Immuno-Oncology Team: 23K Shares Granted to New Biotech Talent - Stock Titan
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 17.1% in March - Defense World
Xilio Therapeutics (XLO) to Release Quarterly Earnings on Monday - Defense World
Head to Head Contrast: Xilio Therapeutics (NASDAQ:XLO) and Janone (NASDAQ:ALTS) - Defense World
Deals In Depth: February 2025 - insights.citeline.com
Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating for Xilio Therapeutics - TipRanks
Xilio advances cancer treatments, secures AbbVie collaboration By Investing.com - Investing.com Australia
Xilio Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time - Marketscreener.com
Xilio Therapeutics inks $50M sales agreement with Leerink Partners - Investing.com India
Xilio Therapeutics inks $50M sales agreement with Leerink Partners By Investing.com - Investing.com UK
Form 424B5 Xilio Therapeutics, Inc. - StreetInsider.com
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Xilio advances cancer treatments, secures AbbVie collaboration - Investing.com India
Xilio Therapeutics, Inc. SEC 10-K Report - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - TradingView
Xilio Therapeutics Provides Pipeline Progress Update and Anticipates Additional Vilastobart Data in Mid-2025 - Nasdaq
Insider Sale Alert: Xilio Therapeutics Inc [XLO] – Is it Time to sell? - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World
Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle
Xilio Therapeutics Inc (XLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
자본화:
|
볼륨(24시간):